Heron Therapeutics Inc (HRTX) Given Consensus Recommendation of “Buy” by Brokerages

Share on StockTwits

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been given an average rating of “Buy” by the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $52.70.

HRTX has been the topic of a number of recent research reports. Cantor Fitzgerald set a $40.00 target price on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. Oppenheimer set a $34.00 target price on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. BidaskClub lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th. ValuEngine raised Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, Evercore ISI boosted their target price on Heron Therapeutics from $56.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, June 21st.

NASDAQ HRTX traded down $0.55 on Friday, reaching $37.05. The stock had a trading volume of 34,009 shares, compared to its average volume of 578,381. Heron Therapeutics has a 12-month low of $14.40 and a 12-month high of $42.90. The stock has a market cap of $3.03 billion, a P/E ratio of 10.56 and a beta of 1.44.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.14. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The company had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $12.82 million. During the same quarter in the previous year, the business earned ($0.80) earnings per share. The firm’s revenue for the quarter was up 103.1% on a year-over-year basis. equities analysts predict that Heron Therapeutics will post -2.22 EPS for the current year.

In related news, President Robert Rosen sold 129,469 shares of the company’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $39.59, for a total transaction of $5,125,677.71. Following the transaction, the president now owns 132,109 shares of the company’s stock, valued at $5,230,195.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Robert Hoffman sold 30,000 shares of the company’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $38.17, for a total value of $1,145,100.00. Following the transaction, the chief financial officer now directly owns 1,280 shares in the company, valued at approximately $48,857.60. The disclosure for this sale can be found here. In the last three months, insiders sold 440,469 shares of company stock worth $17,218,958. Corporate insiders own 16.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in HRTX. Eagle Asset Management Inc. acquired a new position in Heron Therapeutics during the first quarter worth $50,005,000. Carillon Tower Advisers Inc. purchased a new stake in Heron Therapeutics during the first quarter worth $33,651,000. BlackRock Inc. boosted its position in Heron Therapeutics by 29.4% during the second quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock worth $176,563,000 after purchasing an additional 1,032,010 shares in the last quarter. FMR LLC boosted its position in Heron Therapeutics by 6.5% during the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after purchasing an additional 693,699 shares in the last quarter. Finally, Nexthera Capital LP purchased a new stake in Heron Therapeutics during the first quarter worth $11,288,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Google Finance

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply